Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 8-K call announcement, 10-Q stay in one workspace.
SUPN
$42.18
-2.00%
SUPN
· Supernus Pharmaceuticals, Inc.
$42.18
-0.86 (-2.00%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$2.48B
Shares
58.13M
Volume · Oct 1
424.63K
Avg daily vol (3M)
781.5K
All webcasts
Earnings call · FY2026 Q2
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2026 Earnings Call
Forward guidance
2 guided metrics
Management's latest ranges and targets are included below.
Research coverage
3 live sources
Open each available source without leaving this research workspace.
Revenue
$219.06M
+32.4% YoY
Diluted EPS
-$1.01
-352.5% YoY
Net income
-$58.37M
-359.4% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 3, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
ONAPGO net sales
table
Initiated
Full Year 2026
|
$55M – $70M | GAAP | |
|
Trokendi XR and Oxtellar XR net sales
table
Initiated
Full Year 2026
|
$50M – $60M | GAAP |
SEC filing · Item 2.02
8-K earnings release
Filed Aug 3, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 3, 2026 · complete as-filed document
SEC call announcement
8-K call announcement
Filed Aug 3, 2026 · complete as-filed document